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 CURRENTOPINION Unravelling new pathways of sterol metabolism:
lessons learned from in-born errors and cancer
Yuqin Wang and William J. Griffiths
Purpose of review
To update researchers of recently discovered metabolites of cholesterol and of its precursors and to suggest
relevant metabolic pathways.
Recent findings
Patients suffering from inborn errors of sterol biosynthesis, transport and metabolism display unusual
metabolic pathways, which may be major routes in the diseased state but minor in the healthy individual.
Although quantitatively minor, these pathways may still be important in healthy individuals. Four inborn
errors of metabolism, Smith-Lemli-Opitz syndrome, cerebrotendinous xanthomatosis and Niemann Pick
disease types B (NPB) and C (NPC) result from mutations in different genes but can generate elevated
levels of the same sterol metabolite, 7-oxocholesterol, in plasma. How this molecule is metabolized further
is of great interest as its metabolites may have an important role in embryonic development. A second
metabolite, abundant in NPC and NPB diseases, cholestane-3b,5a,6b-triol (3b,5a,6b-triol), has recently
been shown to be metabolized to the corresponding bile acid, 3b,5a,6b-trihydroxycholanoic acid,
providing a diagnostic marker in plasma. The origin of cholestane-3b,5a,6b-triol is likely to be 3b-
hydroxycholestan-5,6-epoxide, which can alternatively be metabolized to the tumour suppressor
dendrogenin A (DDA). In breast tumours, DDA levels are found to be decreased compared with normal
tissues linking sterol metabolism to cancer.
Summary
Unusual sterol metabolites and pathways may not only provide markers of disease, but also clues towards
cause and treatment.
Keywords
bile acid, cholesterol, oxysterol
INTRODUCTION
In vertebrates, cholesterol can be synthesized by all
cells from acetyl-CoA. Following cyclization of squa-
lene to lanosterol via squalene-2,3-epoxide the
pathway divides into two main routes known as
the Bloch and Kandustch–Russell pathways leading
to desmosterol and 7-dehydrocholesterol (7-DHC),
respectively, as the immediate precursors of choles-
terol [1]. Alternatively, cholesterol can be taken up
by cells as lipoproteins and have a dietary origin.
Cholesterol is an essential molecule to maintain
membrane structure and is the metabolic precursor
of bile acids and steroid hormones. It has also been
suggested to be a signallingmolecule in its own right
[2
&&
]. 7-DHC is the precursor of 1a,25-dihydroxyvi-
tamin D3, the biologically active form of vitamin D.
Although the major pathways of cholesterol metab-
olism were delineated in the 20th century [3
&
],
recent studies have revealed new metabolic path-
ways from cholesterol and 7-DHC, generating
metabolites with unexpected biological activity.
7-OXOCHOLSTEROL
7-Oxocholesterol (7-OC), also known as 7-ketocho-
lesterol, is a challenging sterol for biochemists to
analyse as it may be formed by reaction of choles-
terol with oxygen in air [4,5], but can also be formed
endogenously via reaction of cholesterol with reac-
tive oxygen species [6] or from 7-DHC enzymati-
cally [7]. Many analytical scientists have been
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wary of reports of high levels of 7-OC in tissue
and plasma, however, there is now convincing
evidence that 7-OC is abundant in some disease
states.
In agreement with earlier studies by Bjo¨rkhem
et al. [8], Pajares et al. [9] have reported elevated of 7-
OC in plasma of patients suffering from cerebroten-
dinous xanthomatosis (CTX). They used a liquid
chromatography (LC)–tandem mass spectrometry
(MS/MS) method exploiting derivatization to N,N-
dimethylglycine (DMG) esters and electrospray ioni-
zation (ESI). Levels of 7-OC in some CTX patients
prior to treatmentwere ashigh as 1000ng/ml (n¼11,
mean 830ng/ml, range 137– 529ng/ml), compared
with control values of about 10ng/ml (adults n¼75,
median 9.8ng/ml, range 5.3–22.8ng/ml, 5th to 95th
percentile; childrenn¼32,median13.8ng/ml, range
8.3–34.5, 5th to 95th percentile). These values are for
the free sterol as no hydrolysis step was carried out
prior to analysis. CTX is an autosomal recessive dis-
order, where the enzyme cytochrome P450 (CYP)
27A1 is defective. People with CTX often develop
neurological problems in early adulthood, which are
thought to be caused by an abnormal accumulation
of sterols and an increasing number of xanthomas in
brain. In young patients CTXoften present with liver
disease. CYP27A1 is required for bile acid biosynthe-
sis via the conventional pathways, introducing first
an alcohol group and then a carboxylic acid to the
terminal carbonof the sterol side-chain.Wehavealso
found 7-OC to be elevated in CTX plasma and specu-
late that this is a result of upregulation of CYP7A1, as
consequence of reduced negative-feedback by pri-
mary bile acids and use of 7-DHC as the enzyme
substrate [7,8] (Fig. 1).
Pajares et al. [9] also found 7-OC to be elevated
in Niemann Pick disease type C (NPC, n¼16,
range 178–795ng/ml, 95% CI), lysosomal acid
lipase (LAL) deficiency (n¼3, mean 77.7ng/ml,
range 29.6–178ng/ml) and Smith-Lemli-Opitz
syndrome (SLOS, n¼3). More recently, Boenzi
et al. [10
&
] have also found 7-OC to be elevated in
KEY POINTS
 New pathways of sterol metabolism provide biomarkers
for inborn errors of metabolism.
 Newly discovered metabolites have unpredicted
biological properties.
 New sterols provide novel routes to cancer diagnosis
and perhaps treatment.
β
FIGURE 1. Enzymatic or nonenzymatic formation of 7-oxocholesterol, 3b,5a-dihydroxycholest-7-en-6-one and 3b-
hydroxycholestan-5,6-epoxide. The pathways prevalent in SLOS are depicted in the red (upper) and blue (central) boxes, in
CTX in the red (upper) box and in the lysosomal storage diseases NPB, NPC and LAL deficiency in the green (lower) box. The
defective enzymatic step in SLOS is indicated by a horizontal T. ROO., peroxy radical; RO., alkoxy radical.
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patients with Niemann Pick type (NPB) and NPC,
LAL deficiency and SLOS using LC-ESI-MS/MS,
with derivatization to dimethylaminobutyric acid
(DMAB) esters, again in the absence of saponifica-
tion. Control levels of 7-OC were found to be 3.8–
39.8ng/ml (2.5th to 97.5th percentile) with a
median of 16.1 ng/ml (n¼135), in NPC the
median was 86ng/ml (n¼16, range 21.9–963ng/
ml), in NPB only two patients were analysed where
7-OC was 62.8–383ng/ml, in two LAL deficiency
patients 7-OC was 35.5–103ng/ml and in SLOS
patients, the median was 139ng/ml (n¼4, range
76.4–337ng/ml).
SLOS is a congenital disease resulting from a
defect in 7-dehydrocholesterol reductase (DHCR7),
the final enzyme in the Kandustch–Russell path-
way of cholesterol biosynthesis, resulting in ele-
vated levels of 7-DHC in plasma and tissues.
Patients with SLOS present with a broad phenotype
ranging from autistic behaviour in mildly affected
individuals to abnormalities in multiple organs,
dysmorphology and failure to thrive inmore severe
cases [11]. In SLOS, elevated 7-OC can be explained
by enzymatic conversion from abundant 7-DHC by
CYP7A1 (Fig. 1) [7,8,12]. NPC, NPB and LAL defi-
ciency are all lysosomal storage diseases [13
&&
]. In
NPC and NPB, and perhaps LAL deficiency also,
cholesterol accumulates in lysosomes. NPC has a
variable age of onset, with a range of nonspecific
neurological and psychiatric clinical features, it
results from a defect in either NPC1 or NPC2 pro-
teins required for the transport of nonesterified
cholesterol from lysosomes [13
&&
]. NPB, also known
as acid sphingomyelinase deficiencies (ASMDs),
caused bymutations in the SMPD1 gene, is believed
to result from affected cholesterol transfer by NPC2
protein and presents with enlarged liver and spleen
or spleen alone in early childhood. LAL deficiency
results from defective LAL, the enzyme which
hydrolyses cholesterol esters and triglycerides.
Whenever LAL deficiency occurs in infants, it usu-
ally leads to death before 6 months of age; how-
ever, enzyme replacement therapy is now available
[14
&
]. Using LC-MS/MS, DMG derivatization and
atmospheric pressure chemical ionization (APCI),
Romanello et al. [15
&
] analysed control (n¼60,
median 27.08ng/ml, inter quartile range, IQR,
24.31–30.66ng/ml), NPC1 (n¼17, median
137.95ng/ml, IQR 78.16–192.22ng/ml) and NPB
(n¼8, median 120.22ng/ml, IQR 78.69–165.2 ng/
ml) plasma samples for 7-OC. In agreement with
Boenzi et al. [10
&
], they concluded that although
plasma levels of 7-OC could diagnose NPC, it could
not differentiate NPC from NPB. Others have simi-
larly found 7-OC plasma levels to be a diagnostic
for NPC [16,17]. In NPC formation of 7-OC is likely
to be by in vivo free radical oxidation [18
&&
] (Fig. 1),
this is probably true for NPB and LAL deficiency
also. A concern for the analytical chemist when-
ever measuring 7-OC is that it can also be formed
from cholesterol ex vivo [5], this may explain some
of the variation in control values in the three
studies highlighted above. A better diagnostic
would be an enzymatically formed metabolite of
7-OC that could only be formed endogenously.
Mazzacuva et al. [18
&&
] found 3b-hydroxy-7b-N-
acetylglucosaminylchol-5-enoic acid (3b,7b-diH-D5-
BA 7b-GlcNAc) to be elevated in NPC plasma and
suggested its formation from 7-OC via 7b-hydrox-
ycholesterol (7b-HC) (Fig. 2). We also suggested a
pathway for the formation of this unusual bile acid
involving conversion of 7-OC and its 7-oxo metab-
olites to 7b-hydroxy compounds by hydroxysteroid
dehydrogenase (HSD) 11B1 and ultimate conjuga-
tion of the 7b-hydroxy group with N-acetylglucos-
amine (GlcNAc), a reaction known to be specific for
the 7b stereochemistry (Fig. 2) [19]. Many years
earlier we had found 3b-sulphated,7b-GlcNAc con-
jugated D5-bile acids modified with glycine or tau-
rine in NPC urine and current studies in our
laboratory indicate their formation in SLOS patients
also [20]. 3b,7b-diH-D5-BA 7b-GlcNAc, and further
conjugated forms, have potential as a biomarker for
NPC and other disease states wherever 7-OC is ele-
vated. However, Mazzacuva et al. [18
&&
] found a
common mutation inactivating the GlcNAc trans-
ferase enzyme necessary for the formation of the
GlcNAc conjugate. About 20% of Asian and Cauca-
sian populations carry this mutation and fail to
produce GlcNAc conjugates, hence, if these bile
acids were to be used as a biomarker, many cases
would be missed for NPC and also NPB, LAL defi-
ciency and SLOS. However, the suggested biosyn-
thetic pathway for 3b,7b-diH-D5-BA 7b-GlcNAc,
particularly with respect to SLOS, does introduce
some interesting metabolites [19]. One such metab-
olite is (25R)26-hydroxy-7-oxocholesterol (26H,7-
OC), also called 27-hydroxy-7-ketocholesterol
(Fig. 2). 26H,7-OC has been shown to bind to and
activate the G protein-coupled receptor (GPCR)
smoothened (SMO), which transmits signal across
the plasma membrane in the Hedgehog (Hh) signal-
ling pathway. Significantly, SLOS phenocopies dys-
regulated Hh signalling, and defective Hh signalling
has been implicated in dysmorphology associated
with SLOS [21
&
]. In addition to 26H,7O-C, 3b,5a-
dihydroxycholest-7-en-6-one (DHCEO) is a product
of metabolism of 7-DHC in SLOS, in this case via the
intermediate 7-dehydrocholesterol-5a,6a-epoxide
(Fig. 1) [4]. DHCEO is an inhibitor of Hh signalling
and we suggest that dysregulated formation of
Hh-signalling pathway modulatory sterols during
Unravelling new pathways of sterol metabolism Wang and Griffiths
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FIGURE 2. Metabolic transformation of 7-oxocholesterol to 3b,7b-diH-D5-BA 7b-GlcNAc and further conjugates in Smith-Lemli-Opitz
syndrome and Niemann Pick disease type C. The defective enzymatic step in CTX is indicated by a horizontal T. ACOX2, acyl-
coenzyme A oxidase 2; AMACR, alpha-methylacyl-CoA-racemase; BAAT, bile acid-CoA:amino acid N-acyltransferase; BACS, bile acyl
CoA-synthetase; DBP, D bifunctional protein; SPCx, sterol carrier protein x; UGT3A1, UDP glycosyltransferase family 3 member A1.
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development is the cause of some of the phenotypi-
cal features of SLOS [19].
3b-HYDROXYCHOLESTAN-5,6-EPOXIDE
AND CHOLESTANE-3b,5a,6b-TRIOL
3b-Hydroxycholestan-5,6-epoxide (5,6-EC), also
called 5,6-epoxycholesterol or cholesterol-5,6-epox-
ide, like 7-OC can be formed ex vivo from cholesterol
oxidation in air and also in vivo through free radical
reactions [4] (Fig. 1). To-date, no enzyme with cho-
lesterol-5,6-epoxidase activity has been reported.
However, the two isomers 5a,6a-EC and 5b,6b-EC
can both be hydrolysed by cholesterol-5,6-epoxide
hydrolase (ChEH) to cholestane-3b,5a,6b-triol
(3b,5a,6b-triol) (Fig. 3) [22
&&
]. 5,6-EC can also be
hydrolysed under acidic condition to 3b,5a,6b-triol
during sample handling procedures. Like 7-OC,
3b,5a,6b-triol has been suggested as a plasma bio-
marker forNPC.Pajares et al. [9], Boenzi et al. [10
&
] and
Romanello et al. [15
&
] have each found 3b,5a,6b-triol
to be elevated in NPC plasma. Pajares et al. used the
DMG derivative and LC-ESI-MS/MS. In addition to
NPC plasma, 3b,5a,6b-triol was found to be elevated
in plasma from patients with CTX and LAL defi-
ciency. The median control plasma level of
3b,5a,6b-triol was 3.6ng/ml (n¼107, range 0.5–
8ng/ml, 5th to 95th percentile), themeanCTX value
was 43.7ng/ml (n¼11, range 25.4–88.6ng/ml),
whereas NPC values ranged from 62 to 275ng/ml
(95% CI, n¼16) and LAL deficiency from 10.7 to
49.3ng/ml (n¼3). SLOS patients (n¼3) were found
to have normal levels of 3b,5a,6b-triol. Clearly, ele-
vatedplasma levels of3b,5a,6b-triol arenotunique to
NPC. Romanello et al. [15
&
] using a similar derivative
and LC-APCI-MS/MS found plasma levels of NPC
(median 48.44ng/ml, IQR 24.86–60ng/ml, n¼17)
and also NPB (median 35.21ng/ml, IQR 26.12–
60.39ng/ml, n¼8) elevated above control values
(median 9.03ng/ml, IQR 7.38–11.34ng/ml, n¼60).
This data shows that 3b,5a,6b-triol is elevated inboth
NPC and NPB. Boenzi et al. using DMAB derivatiza-
tion and LC-ESI-MS/MS found control plasma levels
of 3b,5a,6b-triol to have a median of 4.1ng/ml in a
range of 1.1–21.9ng/ml (n¼135, 2.5th to 97.5th
percentile). In NPC, the 3b,5a,6b-triol median was
55.3ng/ml in a range 16–608ng/ml (n¼16), in two
NPB patients the range was 52–271ng/ml, in two
patients with LAL deficiency, the range was 22.8–
45.1ng/ml and in four SLOS patients the range was
1.7–7.4ng/ml, similar to levels in control samples
[10
&
]. These three studies clearly indicate that ele-
vated 3b,5a,6b-triol is not unique to NPC. Similar
results have been found by others [23
&&
,24]. In a gas
chromatography (GC)-MS study, Reunert et al. [23
&&
]
analysed 1902 plasma samples from patients with a
suspicion of NPC for 3b,5a,6b-triol. Diagnosis of
patients with elevated 3b,5a,6b-triol was confirmed
by genetic analysis. Twenty-four newmutationswere
identified inNPC1, one inNPC2 and three in SMPD1,
confirming the diagnostic potential of 3b,5a,6b-triol
for the lysosomal storage diseases NPC and NPB.
As is the situation with 7-OC, ex vivo oxidation
of cholesterol can lead to the formation of 5,6-EC,
whichmay be subsequently hydrolysed to 3b,5a,6b-
triol during sample handling procedures. Hence,
elevated 3b,5a,6b-triol may be a consequence of
sample handling and storage. Whenever 3b,5a,6b-
triol is formed in vivo, it is likely to be metabolized
further to a bile acid. In 2016, Mazzacuva et al. [18
&&
]
and Jiang et al. [25
&&
] both reported the identifica-
tion of elevated levels of the unusual bile acid
3b,5a,6b-trihydroxycholanoylglycine (3b,5a,6b-
triHBA 24-G) in plasma of NPC patients. Mazzacuva
et al. found the levels of this bile acid (median
118ng/ml, n¼73) to be more than 10-fold higher
than in controls (9.3ng/ml, n¼84). Jiang et al.
found levels of both the unconjugated and gly-
cine-conjugated bile acid to be elevated in NPC
plasma. They reported reference ranges for the gly-
cine conjugate for controls of less than 5–5.34ng/
ml (n¼1013), NPC1 carriers of less than 5–12.5ng/
ml (n¼130) and NPC1 patients 5.45–294ng/ml
(n¼25). We have performed a similar study and
find that the unconjugated bile acid 3b,5a,6b-trihy-
droxycholanoic acid (3b,5a,6b-triHBA) is also ele-
vated in plasma from patients with NPB and LAL
deficiency [26]. In our study, we identify 3b,5a,6b-
trihydroxycholestanoic acid (3b,5a,6b-triHCa) and
speculate that this acid is further metabolized to
3b,5a,6b-triHBA in the peroxisome (Fig. 3).
DENDROGENIN A
Cholesterol-5,6-epoxide hydrolase (ChEH) will
transform 5,6-EC to 3b,5a,6b-triol. Interestingly,
the enzyme is made up of two subunits, 3b-hydrox-
ysteroid-D8,7-isomerase (D8D7I) and DHCR7, and
is identical to the microsomal protein complex
antiestrogen-binding site (AEBS), which binds to
tamoxifen, the anticancer drug, with high affinity.
Inhibition of ChEH activity by tamoxifen binding
induced cancer cell-differentiation through accumu-
lation of 5,6-EC [22
&&
]. These findings lead Poirot and
colleagues to search for a metabolite of 5,6-EC, other
than those generated from 3b,5a,6b-triol, that may
be display anticancer properties. They discovered
dendrogenin A (DDA), a 6b-histamine adduct of
5a,6a-EC (Fig. 3) [22
&&
]. DDA was found to display
anticancerproperties in vitroand in vivo.DDAis found
inmammalian tissues and at significantly lower con-
centrations in patients with breast tumours than
Unravelling new pathways of sterol metabolism Wang and Griffiths
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normal matched tissue. Analysis of DDA is challeng-
ing. Its polar nature dictates analysis by LC-MS/MS
rather thanGC-MS,however,Noguer et al. [27], using
LC-MS/MS, have experienced serious problems of
carryover between chromatographic runs. This, how-
ever, can be solved by addition of heptafluorobutyric
acid to the mobile phase. This breakthrough should
now allow the discovery of downstream metabolites
FIGURE 3. Metabolism of 3b-hydroxycholestan-5,6-epoxide to the unusual bile acid 3b,5a,6b-triHBA in Niemann Pick
disease type B, Niemann Pick disease type C and lysosomal acid lipase deficiency (green box) or the histamine adduct
dendrogenin A (purple box).
Lipid metabolism and therapy
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ofDDA andperhaps another newmetabolic pathway
of cholesterol metabolism.
CONCLUSION
In recent years the biological significance of non-
enzymatically derived sterols has been realised. How
they are metabolized is an area of great interest
as newly discovered sterol metabolites may have
unexpected biological activity.
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